MRD

A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Enrollment
400 patients (estimated)
Sponsors
University of Rochester
Tags
Minimal Residual Disease (MRD)
Trial Type
Observational
Last Update
4 weeks ago
SparkCures ID
1498
NCT Identifier
NCT01311258

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.